PIPELINE

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in late 2019.

Program portfolio & status

Low molecular weight mutant agnostic approaches